Combination treatment with leptin and pioglitazone in a mouse model of Alzheimer's disease

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Volumn 3, Issue 1, 2017, Pages 92-106

  Fernandez Martos, Carmen M ^a   Atkinson, Rachel A K ^a   Chuah, Meng I ^a   King, Anna E ^a   Vickers, James C ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Alzheimer's disease (AD); Leptin; Pioglitazone; Treatment

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 67; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PIOGLITAZONE; POSTSYNAPTIC DENSITY PROTEIN 95; RECOMBINANT LEPTIN; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; AMNESIA; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; GENE EXPRESSION; GENOTYPE; GLIA; HIPPOCAMPUS; MOUSE; NEOCORTEX; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPATIAL MEMORY; TREATMENT DURATION; UPREGULATION; Y-MAZE TEST;

EID: 85012296959     PISSN: None     EISSN: 23528737     Source Type: Journal    
DOI: 10.1016/j.trci.2016.11.002     Document Type: Article

References (99)

1. [1] Hyman, B.T., Damasio, H., Damasio, A.R., Van Hoesen, G.W., Alzheimer's disease. Annu Rev Public Health 10 (1989), 115–140.
2. [2] Villemagne, V.L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K.A., Salvado, O., et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 12 (2013), 357–367.
3. [3] Chow, V.W., Savonenko, A.V., Melnikova, T., Kim, H., Price, D.L., Li, T., et al. Modeling an anti-amyloid combination therapy for Alzheimer's disease. Sci Transl Med, 2, 2010, 13ra1.
4. [4] Jacobsen, H., Ozmen, L., Caruso, A., Narquizian, R., Hilpert, H., Jacobsen, B., et al. Combined treatment with a BACE inhibitor and anti-Abeta antibody gantenerumab enhances amyloid reduction in APPLondon mice. J Neurosci 34 (2014), 11621–11630.
5. [5] Skerrett, R., Pellegrino, M.P., Casali, B.T., Taraboanta, L., Landreth, G.E., Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor gamma Agonist Treatment Reduces Amyloid beta Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice. J Biol Chem 290 (2015), 21591–21602.
6. [6] Stephens, T.W., Basinski, M., Bristow, P.K., Bue-Valleskey, J.M., Burgett, S.G., Craft, L., et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 377 (1995), 530–532.
7. [7] Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., Friedman, J.M., Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994), 425–432.
8. [8] Greco, SJ, Bryan, KJ, Sarkar, S, Zhu, X, Smith, MA, Ashford, JW, et al. Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 19 (2010), 1155–1167.
9. [9] Fewlass, D.C., Noboa, K., Pi-Sunyer, F.X., Johnston, J.M., Yan, S.D., Tezapsidis, N., Obesity-related leptin regulates Alzheimer's Abeta. FASEB J 18 (2004), 1870–1878.
10. [10] Niedowicz, D.M., Studzinski, C.M., Weidner, A.M., Platt, T.L., Kingry, K.N., Beckett, T.L., et al. Leptin regulates amyloid beta production via the gamma-secretase complex. Biochim Biophys Acta 1832 (2013), 439–444.
11. [11] Marwarha, G, Dasari, B, Prasanthi, JR, Schommer, J, Ghribi, O, Leptin reduces the accumulation of Abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. J Alzheimers Dis 19 (2014), 1007–1019.
12. [12] Perez-Gonzalez, R., Alvira-Botero, M.X., Robayo, O., Antequera, D., Garzon, M., Martin-Moreno, A.M., et al. Leptin gene therapy attenuates neuronal damages evoked by amyloid-beta and rescues memory deficits in APP/PS1 mice. Gene Ther 21 (2014), 298–308.
13. [13] Greco, S.J., Sarkar, S., Johnston, J.M., Zhu, X., Su, B., Casadesus, G., et al. Leptin reduces Alzheimer's disease-related tau phosphorylation in neuronal cells. Biochem Biophys Res Commun 376 (2008), 536–541.
14. [14] Greco, S.J., Sarkar, S., Johnston, J.M., Tezapsidis, N., Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. Biochem Biophys Res Commun 380 (2009), 98–104.
15. [15] Farr, S.A., Banks, W.A., Morley, J.E., Effects of leptin on memory processing. Peptides 27 (2006), 1420–1425.
16. [16] Moult, P.R., Milojkovic, B., Harvey, J., Leptin reverses long-term potentiation at hippocampal CA1 synapses. J Neurochem 108 (2009), 685–696.
17. [17] Harvey, J., Leptin: a diverse regulator of neuronal function. J Neurochem 100 (2007), 307–313.
18. [18] Feinstein, D.L., Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol Ther 5 (2003), 67–73.
19. [19] Heneka, M.T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128 (2005), 1442–1453.
20. [20] Nicolakakis, N., Aboulkassim, T., Ongali, B., Lecrux, C., Fernandes, P., Rosa-Neto, P., et al. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci 28 (2008), 9287–9296.
21. [21] Esposito, K., Ciotola, M., Merante, D., Giugliano, D., Rosiglitazone cools down inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 26 (2006), 1413–1414.
22. [22] Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., Iwamoto, T., Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32 (2011), 1626–1633.
23. [23] Wang, T.D., Chen, W.J., Cheng, W.C., Lin, J.W., Chen, M.F., Lee, Y.T., Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol 98 (2006), 1057–1062.
24. [24] Fernandez-Martos, C.M., Gonzalez, P., Rodriguez, F.J., Acute leptin treatment enhances functional recovery after spinal cord injury. PLoS One, 7, 2012, e35594.
25. [25] Garcia-Alloza, M., Robbins, E.M., Zhang-Nunes, S.X., Purcell, S.M., Betensky, R.A., Raju, S., et al. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24 (2006), 516–524.
26. [26] Kamphuis, W., Mamber, C., Moeton, M., Kooijman, L., Sluijs, J.A., Jansen, A.H., et al. GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS One, 7, 2012, e42823.
27. [27] Jankowsky, J.L., Fadale, D.J., Anderson, J., Xu, G.M., Gonzales, V., Jenkins, N.A., et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13 (2004), 159–170.
28. [28] Fliedner, S., Schulz, C., Lehnert, H., Brain uptake of intranasally applied radioiodinated leptin in Wistar rats. Endocrinology 147 (2006), 2088–2094.
29. [29] Collino, M., Aragno, M., Mastrocola, R., Gallicchio, M., Rosa, A.C., Dianzani, C., et al. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 530 (2006), 70–80.
30. [30] Arnold, J.J., Ahsan, F., Meezan, E., Pillion, D.J., Correlation of tetradecylmaltoside induced increases in nasal peptide drug delivery with morphological changes in nasal epithelial cells. J Pharm Sci 93 (2004), 2205–2213.
31. [31] Chuah, M.I., Tennent, R., Jacobs, I., Response of olfactory Schwann cells to intranasal zinc sulfate irrigation. J Neurosci Res 42 (1995), 470–478.
32. [32] Harris, J.A., West, A.K., Chuah, M.I., Olfactory ensheathing cells: nitric oxide production and innate immunity. Glia 57 (2009), 1848–1857.
33. [33] Adeosun, S.O., Hou, X., Zheng, B., Stockmeier, C., Ou, X., Paul, I., et al. Cognitive deficits and disruption of neurogenesis in a mouse model of apolipoprotein E4 domain interaction. J Biol Chem 289 (2014), 2946–2959.
34. [34] Liu, Y., Staal, J.A., Canty, A.J., Kirkcaldie, M.T., King, A.E., Bibari, O., et al. Cytoskeletal changes during development and aging in the cortex of neurofilament light protein knockout mice. J Comp Neurol 521 (2013), 1817–1827.
35. [35] Fernandez, C.M., Molto, E., Gallardo, N., del Arco, A., Martinez, C., Andres, A., et al. The expression of rat resistin isoforms is differentially regulated in visceral adipose tissues: effects of aging and food restriction. Metabolism 58 (2009), 204–211.
36. [36] Petrov, D., Pedros, I., Artiach, G., Sureda, F.X., Barroso, E., Pallas, M., et al. High-fat diet-induced deregulation of hippocampal insulin signaling and mitochondrial homeostasis deficiences contribute to Alzheimer disease pathology in rodents. Biochim Biophys Acta 1852 (2015), 1687–1699.
37. [37] Fernandez-Martos, C.M., Gonzalez-Fernandez, C., Gonzalez, P., Maqueda, A., Arenas, E., Rodriguez, F.J., Differential expression of Wnts after spinal cord contusion injury in adult rats. PLoS One, 6, 2011, e27000.
38. [38] Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25 (2001), 402–408.
39. [39] Gonzalez-Fernandez, C., Fernandez-Martos, C.M., Shields, S.D., Arenas, E., Javier Rodriguez, F., Wnts are expressed in the spinal cord of adult mice and are differentially induced after injury. J Neurotrauma 31 (2014), 565–581.
40. [40] Liu, Y., Atkinson, R.A., Fernandez-Martos, C.M., Kirkcaldie, M.T., Cui, H., Vickers, J.C., et al. Changes in TDP-43 expression in development, aging, and in the neurofilament light protein knockout mouse. Neurobiol Aging 36 (2015), 1151–1159.
41. [41] Fernandez-Martos, C.M., King, A.E., Atkinson, R.A., Woodhouse, A., Vickers, J.C., Neurofilament light gene deletion exacerbates amyloid, dystrophic neurite, and synaptic pathology in the APP/PS1 transgenic model of Alzheimer's disease. Neurobiol Aging 36 (2015), 2757–2767.
42. [42] Mitew, S., Kirkcaldie, M.T., Dickson, T.C., Vickers, J.C., Neurites containing the neurofilament-triplet proteins are selectively vulnerable to cytoskeletal pathology in Alzheimer's disease and transgenic mouse models. Front Neuroanat, 7, 2013, 30.
43. [43] Collins, J.M., King, A.E., Woodhouse, A., Kirkcaldie, M.T., Vickers, J.C., The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease. Exp Neurol 267 (2015), 219–229.
44. [44] Franklin, K.B.J., Paxinos, G., The Mouse Brain in Stereotaxic Coordinates. 2008, Academic Press, New York, NY.
45. [45] Dickson, T.C., King, C.E., McCormack, G.H., Vickers, J.C., Neurochemical diversity of dystrophic neurites in the early and late stages of Alzheimer's disease. Exp Neurol 156 (1999), 100–110.
46. [46] Vickers, J.C., Chin, D., Edwards, A.M., Sampson, V., Harper, C., Morrison, J., Dystrophic neurite formation associated with age-related beta amyloid deposition in the neocortex: clues to the genesis of neurofibrillary pathology. Exp Neurol 141 (1996), 1–11.
47. [47] Le, R., Cruz, L., Urbanc, B., Knowles, R.B., Hsiao-Ashe, K., Duff, K., et al. Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer disease: implications for neural system disruption. J Neuropathol Exp Neurol 60 (2001), 753–758.
48. [48] Woodhouse, A., Vickers, J.C., Adlard, P.A., Dickson, T.C., Dystrophic neurites in TgCRND8 and Tg2576 mice mimic human pathological brain aging. Neurobiol Aging 30 (2009), 864–874.
49. [49] Searcy, J.L., Phelps, J.T., Pancani, T., Kadish, I., Popovic, J., Anderson, K.L., et al. Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease. J Alzheimers Dis 30 (2012), 943–961.
50. [50] Papadopoulos, P., Rosa-Neto, P., Rochford, J., Hamel, E., Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-beta and cerebrovascular pathology. PLoS One, 8, 2013, e68612.
51. [51] Xu, S., Guan, Q., Wang, C., Wei, X., Chen, X., Zheng, B., et al. Rosiglitazone prevents the memory deficits induced by amyloid-beta oligomers via inhibition of inflammatory responses. Neurosci Lett 578 (2014), 7–11.
52. [52] Escribano, L., Simon, A.M., Gimeno, E., Cuadrado-Tejedor, M., Lopez de Maturana, R., Garcia-Osta, A., et al. Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 35 (2010), 1593–1604.
53. [53] O'Reilly, J.A., Lynch, M., Rosiglitazone improves spatial memory and decreases insoluble Abeta(1-42) in APP/PS1 mice. J Neuroimmune Pharmacol 7 (2012), 140–144.
54. [54] Toledo, E.M., Inestrosa, N.C., Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol Psychiatry 15 (2010), 272–285 228.
55. [55] Yu, Y., Li, X., Blanchard, J., Li, Y., Iqbal, K., Liu, F., et al. Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice. J Neural Transm (Vienna) 122 (2015), 593–606.
56. [56] Mandrekar-Colucci, S., Karlo, J.C., Landreth, G.E., Mechanisms underlying the rapid peroxisome proliferator-activated receptor-gamma-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J Neurosci 32 (2012), 10117–10128.
57. [57] Camacho, I.E., Serneels, L., Spittaels, K., Merchiers, P., Dominguez, D., De Strooper, B., Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci 24 (2004), 10908–10917.
58. [58] Perez, M.J., Quintanilla, R.A., Therapeutic Actions of the Thiazolidinediones in Alzheimer's Disease. PPAR Res, 2015, 2015, 957248.
59. [59] Lacombe, P., Mathews, P.M., Schmidt, S.D., Breidert, T., Heneka, M.T., Landreth, G.E., et al. Effect of anti-inflammatory agents on transforming growth factor beta over-expressing mouse brains: a model revised. J Neuroinflammation, 1, 2004, 11.
60. [60] Pedersen, W.A., McMillan, P.J., Kulstad, J.J., Leverenz, J.B., Craft, S., Haynatzki, G.R., Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 199 (2006), 265–273.
61. [61] Yan, Q., Zhang, J., Liu, H., Babu-Khan, S., Vassar, R., Biere, A.L., et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23 (2003), 7504–7509.
62. [62] Amantea, D., Tassorelli, C., Russo, R., Petrelli, F., Morrone, L.A., Bagetta, G., et al. Neuroprotection by leptin in a rat model of permanent cerebral ischemia: effects on STAT3 phosphorylation in discrete cells of the brain. Cell Death Dis, 2, 2011, e238.
63. [63] Yamanaka, M., Ishikawa, T., Griep, A., Axt, D., Kummer, M.P., Heneka, M.T., PPARgamma/RXRalpha-induced and CD36-mediated microglial amyloid-beta phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J Neurosci 32 (2012), 17321–17331.
64. [64] Denner, L.A., Rodriguez-Rivera, J., Haidacher, S.J., Jahrling, J.B., Carmical, J.R., Hernandez, C.M., et al. Cognitive enhancement with rosiglitazone links the hippocampal PPARgamma and ERK MAPK signaling pathways. J Neurosci 32 (2012), 16725a–16735a.
65. [65] Escribano, L., Simon, A.M., Perez-Mediavilla, A., Salazar-Colocho, P., Del Rio, J., Frechilla, D., Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun 379 (2009), 406–410.
66. [66] To, A.W., Ribe, E.M., Chuang, T.T., Schroeder, J.E., Lovestone, S., The epsilon3 and epsilon4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice. PLoS One, 6, 2011, e16991.
67. [67] Liu, F., Li, B., Tung, E.J., Grundke-Iqbal, I., Iqbal, K., Gong, C.X., Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation. Eur J Neurosci 26 (2007), 3429–3436.
68. [68] Lovestone, S., Davis, D.R., Webster, M.T., Kaech, S., Brion, J.P., Matus, A., et al. Lithium reduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations. Biol Psychiatry 45 (1999), 995–1003.
69. [69] Greco, S.J., Sarkar, S., Casadesus, G., Zhu, X., Smith, M.A., Ashford, J.W., et al. Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells. Neurosci Lett 455 (2009), 191–194.
70. [70] Howlett, D.R., Bowler, K., Soden, P.E., Riddell, D., Davis, J.B., Richardson, J.C., et al. Abeta deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's disease. Histol Histopathol 23 (2008), 67–76.
71. [71] Vickers, J.C., Mitew, S., Woodhouse, A., Fernandez-Martos, C.M., Kirkcaldie, M.T., Canty, A.J., et al. Defining the earliest pathological changes of Alzheimer's disease. Curr Alzheimer Res 13 (2016), 281–287.
72. [72] Hof, P.R., Morrison, J.H., Neocortical neuronal subpopulations labeled by a monoclonal antibody to calbindin exhibit differential vulnerability in Alzheimer's disease. Exp Neurol 111 (1991), 293–301.
73. [73] Morrison, J.H., Lewis, D.A., Campbell, M.J., Huntley, G.W., Benson, D.L., Bouras, C., A monoclonal antibody to non-phosphorylated neurofilament protein marks the vulnerable cortical neurons in Alzheimer's disease. Brain Res 416 (1987), 331–336.
74. [74] Vickers, J.C., Costa, M., The neurofilament triplet is present in distinct subpopulations of neurons in the central nervous system of the guinea-pig. Neuroscience 49 (1992), 73–100.
75. [75] Vickers, J.C., Riederer, B.M., Marugg, R.A., Buee-Scherrer, V., Buee, L., Delacourte, A., et al. Alterations in neurofilament protein immunoreactivity in human hippocampal neurons related to normal aging and Alzheimer's disease. Neuroscience 62 (1994), 1–13.
76. [76] Vickers, J.C., Delacourte, A., Morrison, J.H., Progressive transformation of the cytoskeleton associated with normal aging and Alzheimer's disease. Brain Res 594 (1992), 273–278.
77. [77] Duyckaerts, C., Sazdovitch, V., Seilhean, D., Delaere, P., Hauw, J.J., A brain bank in a neuropathology laboratory (with some emphasis on diagnostic criteria). J Neural Transm Suppl 39 (1993), 107–118.
78. [78] Scheff, S.W., Price, D.A., Schmitt, F.A., Mufson, E.J., Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 27 (2006), 1372–1384.
79. [79] Terry, R.D., Masliah, E., Salmon, D.P., Butters, N., DeTeresa, R., Hill, R., et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30 (1991), 572–580.
80. [80] Knafo, S., Alonso-Nanclares, L., Gonzalez-Soriano, J., Merino-Serrais, P., Fernaud-Espinosa, I., Ferrer, I., et al. Widespread changes in dendritic spines in a model of Alzheimer's disease. Cereb Cortex 19 (2009), 586–592.
81. [81] Mitew, S., Kirkcaldie, M.T., Dickson, T.C., Vickers, J.C., Altered synapses and gliotransmission in Alzheimer's disease and AD model mice. Neurobiol Aging 34 (2013), 2341–2351.
82. [82] Pedros, I., Petrov, D., Allgaier, M., Sureda, F., Barroso, E., Beas-Zarate, C., et al. Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease. Biochim Biophys Acta 1842 (2014), 1556–1566.
83. [83] Harvey, J., Solovyova, N., Irving, A., Leptin and its role in hippocampal synaptic plasticity. Prog Lipid Res 45 (2006), 369–378.
84. [84] Guimond, D., Diabira, D., Porcher, C., Bader, F., Ferrand, N., Zhu, M., et al. Leptin potentiates GABAergic synaptic transmission in the developing rodent hippocampus. Front Cell Neurosci, 8, 2014, 235.
85. [85] Ahima, R.S., Bjorbaek, C., Osei, S., Flier, J.S., Regulation of neuronal and glial proteins by leptin: implications for brain development. Endocrinology 140 (1999), 2755–2762.
86. [86] Stranahan, A.M., Lee, K., Martin, B., Maudsley, S., Golden, E., Cutler, R.G., et al. Voluntary exercise and caloric restriction enhance hippocampal dendritic spine density and BDNF levels in diabetic mice. Hippocampus 19 (2009), 951–961.
87. [87] Udagawa, J., Hashimoto, R., Suzuki, H., Hatta, T., Sotomaru, Y., Hioki, K., et al. The role of leptin in the development of the cerebral cortex in mouse embryos. Endocrinology 147 (2006), 647–658.
88. [88] Udagawa, J., Hatta, T., Hashimoto, R., Otani, H., Roles of leptin in prenatal and perinatal brain development. Congenit Anom (Kyoto) 47 (2007), 77–83.
89. [89] Oakley, H., Cole, S.L., Logan, S., Maus, E., Shao, P., Craft, J., et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26 (2006), 10129–10140.
90. [90] Shao, C.Y., Mirra, S.S., Sait, H.B., Sacktor, T.C., Sigurdsson, E.M., Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Abeta and tau pathology in transgenic mouse models of Alzheimer's disease. Acta Neuropathol 122 (2011), 285–292.
91. [91] Zhang, F., Jiang, L., Neuroinflammation in Alzheimer's disease. Neuropsychiatr Dis Treat 11 (2015), 243–256.
92. [92] Munshi, S., Clinicotherapeutic Potential of Leptin in Alzheimer's Disease and Parkinson's Disease. Asian J Neurosci, 2014, 2014, 9.
93. [93] Carson, M.J., Doose, J.M., Melchior, B., Schmid, C.D., Ploix, C.C., CNS immune privilege: hiding in plain sight. Immunol Rev 213 (2006), 48–65.
94. [94] Jaffar, S., Counts, S.E., Ma, S.Y., Dadko, E., Gordon, M.N., Morgan, D., et al. Neuropathology of mice carrying mutant APP(swe) and/or PS1(M146L) transgenes: alterations in the p75(NTR) cholinergic basal forebrain septohippocampal pathway. Exp Neurol 170 (2001), 227–243.
95. [95] Aguilar-Valles, A., Inoue, W., Rummel, C., Luheshi, G.N., Obesity, adipokines and neuroinflammation. Neuropharmacology 96 (2015), 124–134.
96. [96] Lafrance, V., Inoue, W., Kan, B., Luheshi, G.N., Leptin modulates cell morphology and cytokine release in microglia. Brain Behav Immun 24 (2010), 358–365.
97. [97] Finkel, T., Holbrook, N.J., Oxidants, oxidative stress and the biology of ageing. Nature 408 (2000), 239–247.
98. [98] Rosenberg, G.A., Blood-Brain Barrier Permeability in Aging and Alzheimer's Disease. J Prev Alzheimers Dis 1 (2014), 138–139.
99. [99] Olivera, G.C., Ren, X., Vodnala, S.K., Lu, J., Coppo, L., Leepiyasakulchai, C., et al. Nitric Oxide Protects against Infection-Induced Neuroinflammation by Preserving the Stability of the Blood-Brain Barrier. Plos Pathog, 12, 2016, e1005442.